Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
Clinical Lymphoma Myeloma and Leukemia · 2024-06 · 24 (6) · e235-e256.e2
DOI: 10.1016/j.clml.2024.02.007 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024-06. Verfasst von Samuel Yamshon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY. Electronic address: sjy9001@med.cornell.edu. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Non-Hodgkin. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The application of CD19-directed chimeric antigen receptor T (CAR T) cell therapy has improved outcomes for thousands of patients with non-Hodgkin B cell lymphoma (NHL). The toxicities associated with various CAR T cell products, however, can be severe and difficult to anticipate. METHODS: In this systematic review and meta-analysis, we set out to determine whether there are measurable differences in common toxicities, including cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS), cytopenias, and infections, between CAR T products that are commercially available for the treatment of NHL. RESULTS: After a stringent study selection process, we used a cohort of 1364 patients enrolled in 15 prospective clinical trials investigating the use of axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel). We found that the rates of CRS and ICANS were significantly higher with axi-cel as compared to both liso-cel and tisa-cel. Conversely, we demonstrated that rates of all-grade and severe neutropenia were significantly greater with liso-cel. Febrile neutropenia and all-grade infection rates did not differ significantly between products though rates of severe infection were increased with axi-cel. CONCLUSIONS: Overall, this study serves as the first to delineate toxicity profiles associated with various available CAR T products. By better understanding associated toxicities, it may become possible to tailor therapies towards individual patients and anticipate the development of toxicities at earlier stages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY. Electronic address: sjy9001@med.cornell.edu.
- Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY.
- Division of Biostatistics and Epidemiology, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY.
- Samuel J. Wood Library & C.V. Starr Biomedical Information Center, Weill Cornell Medicine, New York, NY.
- Department of Pharmacy, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY.
Zitieren
APA
Yamshon, S., Gribbin, C., Alhomoud, M., Chokr, N., Chen, Z., Demetres, M., Pasciolla, M., Leonard, J., Shore, T., & Martin, P. (2024). Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia, 24(6), e235-e256.e2. https://doi.org/10.1016/j.clml.2024.02.007
Vancouver
Yamshon S, Gribbin C, Alhomoud M, Chokr N, Chen Z, Demetres M, et al. Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia. 2024;24(6):e235-e256.e2. doi:10.1016/j.clml.2024.02.007
BibTeX
@article{Yamshon2024,
author = {Yamshon, Samuel and Gribbin, Caitlin and Alhomoud, Mohammad and Chokr, Nora and Chen, Zhengming and Demetres, Michelle and Pasciolla, Michelle and Leonard, John and Shore, Tsiporah and Martin, Peter},
title = {Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
volume = {24},
number = {6},
pages = {e235--e256.e2},
doi = {10.1016/j.clml.2024.02.007}
}
EUVIMED